Hunter Associates Investment Management LLC Has $235,000 Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Hunter Associates Investment Management LLC decreased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 25.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 15,800 shares of the company’s stock after selling 5,500 shares during the period. Hunter Associates Investment Management LLC’s holdings in Elanco Animal Health were worth $235,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Primecap Management Co. CA increased its holdings in shares of Elanco Animal Health by 0.4% in the third quarter. Primecap Management Co. CA now owns 49,168,659 shares of the company’s stock worth $552,656,000 after acquiring an additional 172,205 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Elanco Animal Health by 0.7% in the third quarter. Vanguard Group Inc. now owns 49,001,441 shares of the company’s stock worth $550,776,000 after acquiring an additional 362,152 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Elanco Animal Health by 6.6% in the first quarter. BlackRock Inc. now owns 26,217,917 shares of the company’s stock worth $684,027,000 after acquiring an additional 1,631,045 shares in the last quarter. Black Creek Investment Management Inc. increased its holdings in shares of Elanco Animal Health by 12.8% in the third quarter. Black Creek Investment Management Inc. now owns 15,523,457 shares of the company’s stock worth $174,484,000 after acquiring an additional 1,759,556 shares in the last quarter. Finally, Shapiro Capital Management LLC increased its holdings in shares of Elanco Animal Health by 1,763.6% in the fourth quarter. Shapiro Capital Management LLC now owns 13,522,352 shares of the company’s stock worth $165,243,000 after acquiring an additional 12,796,752 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on ELAN. Barclays increased their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. The Goldman Sachs Group raised their price objective on Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research report on Tuesday, February 27th. Stifel Nicolaus raised Elanco Animal Health from a “hold” rating to a “buy” rating and lifted their price target for the stock from $13.00 to $20.00 in a report on Friday, January 5th. TheStreet raised Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Finally, Morgan Stanley lifted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Elanco Animal Health Stock Down 4.6 %

ELAN traded down $0.62 during midday trading on Friday, reaching $12.95. 5,742,048 shares of the company were exchanged, compared to its average volume of 3,557,223. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.35 and a current ratio of 2.75. The company’s fifty day moving average price is $15.66 and its 200 day moving average price is $13.65. The company has a market cap of $6.38 billion, a price-to-earnings ratio of -5.18, a price-to-earnings-growth ratio of 1.42 and a beta of 1.29. Elanco Animal Health Incorporated has a one year low of $7.88 and a one year high of $16.88.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.02). Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company posted $0.19 earnings per share. Elanco Animal Health’s revenue for the quarter was up 5.1% on a year-over-year basis. As a group, analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Buying and Selling

In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the transaction, the director now owns 185,000 shares of the company’s stock, valued at approximately $2,985,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.40% of the stock is currently owned by company insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.